News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daiichi Sankyo Co Ltd. Selects IntraLinks, Inc. for Secure Information Sharing



1/19/2010 12:02:00 PM

TOKYO--(Marketwire - January 19, 2010) - IntraLinks, the leading provider of critical information exchange solutions, announced today that Daiichi Sankyo has selected IntraLinks as the company's information sharing solution. Daiichi Sankyo now joins the world's top 10 pharmaceutical companies that already leverage IntraLinks' solution.

With more than 100 years of scientific expertise across a wide range of therapeutic categories, Daiichi Sankyo draws upon a rich legacy of innovation and a robust pipeline of promising new compounds. Today Daiichi Sankyo faces many new challenges including developing new innovative pharmaceuticals and ongoing communication with global regulatory bodies. Prior to selecting IntraLinks, Daiichi Sankyo considered a number of information sharing platforms for managing their highly confidential business information in a multi-lingual environment without imposing additional demand on the company's IT resources. With IntraLinks, Daiichi Sankyo now manages, organizes, tracks and shares critical information both inside and outside the enterprise with 24/7/365 live system support around the world.

"We are extremely pleased to introduce the IntraLinks solution to facilitate secure and speedy information exchange inside and outside the company's firewall. We plan to use IntraLinks strategically across diverse departments in the near future to raise our standard of operational efficiency," said Mr. Yasuhiro Ikeda, General Manager, IT Strategy Department of Daiichi Sankyo.

"We are delighted that IntraLinks has been selected by Daiichi Sankyo. As a Software-as-a-Service solution, IntraLinks requires no additional hardware, software, or additional demands on IT resources. Hence our customers can gain tremendous cost efficiencies with a solution that can be implemented in near real-time. We believe the decision by Daiichi Sankyo is yet another testament to the effectiveness of our solution, which has already been widely deployed within the pharmaceutical industry," said Rob Mullen, EVP of Worldwide Sales for IntraLinks.

About IntraLinks

IntraLinks provides on-demand solutions for businesses to securely collaborate, communicate and exchange critical information inside and outside the enterprise. For more than a decade, 750,000 professionals from more than 90,000 organizations have relied on IntraLinks to accelerate workflow, optimize business processes and realize new profit potential. IntraLinks counts 800 of the Fortune 1000 as clients, including AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more information, visit www.intralinks.com.

About Daiichi Sankyo Company, Limited

A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.


CONTACT:
Alison Koski
Text100
212-331-8436
AlisonK@text100.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES